Q2 2024 · 13F-HR
Decheng Capital LLCholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089453
$326.3M
Reported value
24
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $172.3M | 52.8% | 5,458,810 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $20.3M | 6.22% | 6,950,239 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc | $13.2M | 4.06% | 869,790 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc. | $12.6M | 3.85% | 3,070,442 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $12.1M | 3.70% | 65,772 | Common | SOLE |
| G10830100 | BYSI | BeyondSpring Inc. | $11.9M | 3.65% | 4,958,143 | Common | SOLE |
| 452327109 | ILMN | Illumnia, Inc. | $11.4M | 3.48% | 108,767 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $10.6M | 3.25% | 179,098 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $8.8M | 2.68% | 850,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $7.7M | 2.35% | 400,000 | Common | SOLE |
| G4444C102 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $7.3M | 2.24% | 166,600 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $7.3M | 2.24% | 347,835 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $7.1M | 2.17% | 157,958 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $5.1M | 1.56% | 94,043 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $4.4M | 1.34% | 98,558 | Common | SOLE |
| 05153U107 | AURA | Aura Biosciences, Inc. | $3.9M | 1.19% | 515,555 | Common | SOLE |
| 29446K106 | EQ | Equillium Inc. | $3.1M | 0.94% | 4,447,308 | Common | SOLE |
| 81663L200 | WGS | GeneDx Holdings Corp. | $2.7M | 0.83% | 103,604 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $2.5M | 0.77% | 69,767 | Common | SOLE |
| 747324101 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $1.1M | 0.33% | 326,810 | Common | SOLE |
| 04963C209 | ATRC | AtriCure Inc. | $610,168 | 0.19% | 26,797 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $278,612 | 0.09% | 18,127 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc. | $103,369 | 0.03% | 646,057 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $64,959 | 0.02% | 1,177 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.